You may find more results for this query on our sister sites: GenomeWeb and Precision Oncology News.
Several analysts said that the decision by UHC, the largest private payor in the US, will especially benefit Natera.
The regulatory submission triggers a milestone payment, and Invitae will issue 5 million shares of its common stock to former ArcherDx securityholders.
The firms said they are collaborating to facilitate genetic testing to support early diagnosis of GM1, a rare monogenic recessive lysosomal storage disease.
The firm generated $68.7 million in revenues compared to $56.5 million in Q3 2019 and exceeded the consensus Wall Street estimate.
The firms will conduct PacBio whole-genome sequencing on epilepsy patients to generate variant profiles that can help the development of diagnostic assays.
The investment bank also moved the company's stock price target to $45 from a prior target of $25 and noted several recent acquisitions by Invitae.
An Invitae-led retrospective study found almost a third of cancer patients who underwent germline genetic testing after tumor sequencing had pathogenic variants.
Natera claims that several Genosity products infringe its US Patent No. 10,732,220, titled "Methods for Simultaneous Amplification of Target Loci."
Last month, the court also ordered two separate patent lawsuits filed by Natera against ArcherDx this year to be consolidated into one.
The merger brings tumor profiling and liquid biopsy technologies for predicting and monitoring therapeutic response to Invitae's service offerings.